Table 2 The results for primary and secondary outcomes analyzed separately for purine- and non-purine-like xanthine oxidase inhibitors (XOI)

 Major adverse cardiovascular events

0.65 (0.41 to 1.05), P = 0.076, I² = 9% (P = 0.354), 65 studies

1.13 (0.40 to 3.19), P = 0.824, I² = 18% (0.290), 19 studies

 Death

0.94 (0.62 to 1.44), P = 0.785, I² = 0% (P = 0.525), 74 studies

0.71 (0.15 to 3.40), P = 0.671, I² = 0%, (P = 0.956), 19 studies

 Myocardial infarction or urgent revascularization procedure

0.38 (0.17 to 0.83), P = 0.015, I² = 0% (P = 0.700), 62 studies

2.76 (0.62 to 12.35), P = 0.185, I² = 0% (P = 0.502), 19 studies

 Stroke

0.73 (0.16 to 3.29), P = 0.678, I² = 2% (P = 0.361), 60 studies

0.54 (0.07 to 4.07), P = 0.551, I² = 11% (P = 0.337), 19 studies

 Cardiovascular death

0.86 (0.50 to 1.46), P = 0.570, I² = 0% (P = 0.587), 66 studies

0.45 (0.06 to 3.48), P = 0.445, I² = 0% (P = 0.789), 19 studies

 New/worsening hypertension

0.32 (0.18 to 0.58), P < 0.001, I² = 0% (P = 0.737), 55 studies

0.70 (0.43 to 1.12), P = 0.136, I² = 13% (P = 0.329), 19 studies

 New/worsening heart failure

0.90 (0.66 to 1.24), P = 0.539, I² = 72% (P = 0.006), 59 studies

1.79 (0.43 to 7.49), P = 0.423, I² = 0% (P = 0.451), 18 studies

 Arrhythmias

1.95 (0.20 to 18.72), P = 0.564, I² = 25%, (P = 0.264), 54 studies

0.80 (0.25 to 2.56), P = 0.708, I² = 0% (P = 0.681), 19 studies

 Total cardiovascular events

0.57 (0.46 to 0.72), P < 0.001, I² = 60% (P < 0.001), 65 studies; D-L: 0.48 (0.31 to 0.75), P = 0.001, I² = 55% (P = 0.001)

0.90 (0.62 to 1.30), P = 0.562, I² = 0% (P = 0.734), 19 studies

 Serious cardiovascular events

0.59 (0.46 to 0.76), P < 0.001, I² = 50% (P = 0.011), 65 studies; D-L: 0.56 (0.36 to 0.86), P = 0.009, I² = 44% (P = 0.028)

1.04 (0.58 to 1.87), P = 0.901, I² = 0% (P = 0.967), 19 studies

 Serious adverse events

0.88 (0.70 to 1.10), P = 0.280, I² = 18% (P = 0.176), 64 studies

1.12 (0.75 to 1.66), P = 0.587, 0% (P = 0.679), 19 studies